Erratum

COUP-TFII promotes colorectal carcinoma resistance to doxorubicin involving inhibition of epithelial-mesenchymal transition: Am J Transl Res. 2016; 8(9): 3921-3929

Xiang Wang1*, Rui Jiang2*, Enhai Cui2, Wenming Feng1, Huihui Guo1, Donghua Gu2, Chengwu Tang1, Tao Xue1, Ying Bao1

1First Affiliated Hospital, Huzhou Teachers College, The First People’s Hospital of Huzhou, Huzhou 313000, China; 2Huzhou Central Hospital, Huzhou 313000, China. *Equal contributors.

Received April 2, 2018; Accepted July 5, 2018; Epub August 15, 2018; Published August 30, 2018

In this article published in AJTR, a minor concern regarding the title “COUP-TFII suppresses colorectal carcinoma resistance to doxorubicin involving inhibition of epithelial-mesenchymal transition”, we had changed it into “COUP-TFII promotes colorectal carcinoma resistance to doxorubicin involving inhibition of epithelial-mesenchymal transition”.

In the abstract section, we had revised two sentences. The first is “Besides, COUP-TFII knock-down resulted in significantly increased sensitivity to doxorubicin in all of CRC cell lines, but Twist knock-down presented totally reversed results” revised to “Besides, COUP-TFII knock-down resulted in significantly increased sensitivity to doxorubicin in all of CRC cell lines, but Twist knock-down presented totally reversed this effect”. The second is “Furthermore, COUP-TFII knock-down promoted epithelial-mesenchymal transition in (EMT) CRC cell lines” revised to “Furthermore, COUP-TFII knock-down promoted mesenchymal-epithelial transition (MET) in CRC cell lines”. The last is “After doxorubicin treatment, immediately decreased COUP-TFII expression significantly promotes CRC cells survival outcomes by suppressing EMT” revised to “After doxorubicin treatment, immediately decreased COUP-TFII expression significantly suppresses CRC cells survival outcomes by suppressing EMT”.

In the last part of introduction section, “Our results suggest that continuous exposure to doxorubicin promoted CRC cell lines EMT through down regulated COUP-TFII expression” revised to “Our results suggest that COUP-TFII could promote CRC cells resistance to doxorubicin through inhibition of EMT”.

In the second of results section, the titles “COUP-TFII knockdown promoting doxorubicin resistance” revised to “COUP-TFII promoting doxorubicin resistance”, and we added sentence “positively related the IC50” behind Figure 1B.

In the fourth and the last discussion sections, “In the study, suppressed Vimentin expression and up-regulated E-cadherin expression were presented in the COUP-TFII knockdown CRC cell lines, which hinted that COUP-TFII was a suppressor of EMT” revised to “In the study, suppressed Vimentin expression and up-regulated E-cadherin expression were presented in the COUP-TFII knockdown CRC cell lines, which hinted that COUP-TFII would promote EMT”. The last section, “In summary, immediately decreased COUP-TFII expression significantly promotes CRC cells survival outcomes following doxorubicin treatment. Moreover, the mechanism underlying COUP-TFII regulating CRC resistance to doxorubicin is suppressing EMT” revised to “In
Colorectal carcinoma resistance to doxorubicin

summary, highly COUP-TFII expression significantly promotes CRC cells survival outcomes following doxorubicin treatment. Moreover, the mechanism underlying COUP-TFII regulating CRC resistance to doxorubicin is promoting EMT.

Address correspondence to: Ying Bao, First Affiliated Hospital, Huzhou Teachers College, The First People’s Hospital of Huzhou, Huzhou 313000, China. Tel: +86572-2023728; Fax: +86572-2023728; E-mail: baoying2222@126.com